超低剂量沙利度胺治疗多发性骨髓瘤的临床研究  

Clinical study of ultra low dose thalidomide for myeloma

作　　者：王学文[1] 

机构地区：[1]南京军区南京总医院血液病科,江苏南京210002

出　　处：《现代肿瘤医学》2011年第6期1253-1255,共3页Journal of Modern Oncology

摘　　要：沙利度胺是治疗多发性骨髓瘤(MM)的有效药物,其抗MM治疗的合适剂量尚未完全确定,且无明确的剂量-反应关系。该药的不良反应与剂量相关。超低剂量沙利度胺(25mg/d,T25)可使大多数患者耐受,并在单用或联用(+小剂量环磷酰胺+小剂量地塞米松)时显示有效。尤其适用于老年、体衰和不耐受的患者,并提供更长时间的维持治疗。Thalidomide is an effective drug in myeloma,but its exact mode of action is unclear.The optimal dose of thalidomide as anti-myeloma therapy is not fully established.There is not a clear dose-response relationship between thalidomide dose and myeloma response.Thalidomide has many side effects,some are dose-related.Initiating thalidomide treatment at a low dose may make treatment tolerable to a larger number of patients than with current standard dose regimens.The T25 ＋/-low dose cyclophosphamide ＋/-low dose dexamethasone may have some efficacy for myeloma.It may be appropriate to initiate thalidomide therapy at T25 in elderly poor performance patients.The use of T25 may enable patients to continue maintenance treatment for longer than with conventional dose thalidomide.

关 键 词：沙利度胺 超低剂量沙利度胺 骨髓瘤 老年 体能状态 

分 类 号：R733.3[医药卫生—肿瘤]